KOSDAQBiotech & Pharma206650

EuBiologics

₩8,560▼ 1.04%2026-11-18 close
Market Cap
₩311.2B
Turnover
₩1.4B
Volume
160K
Shares out.
36.4M
PER
6.8×
PBR
1.4×
EPS
₩1,186
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Cholera Vaccine Profits Fund the Diversification Push

EuBiologics posted a 40.7% operating margin in 2025 on cholera vaccine supply to international agencies, has grown revenue for two straight quarters since its first-quarter 2026 low, and now depends on typhoid and meningococcal vaccine launches to diversify.

  1. 1

    Revenue reached KRW 149.2 billion in 2025, up 55.4% year on year, and operating profit reached KRW 60.7 billion, up 76.8%. BioNews (The Bio) described the year as a record performance.

  2. 2

    Revenue bottomed at KRW 15.6 billion in the first quarter of 2026, then rose to KRW 33.2 billion in the second quarter and KRW 49.6 billion in the third. Third-quarter operating profit was KRW 21.9 billion.

  3. 3

    Using its second plant, the company raised annual cholera vaccine capacity to about 90 million doses, and plans to invest about KRW 111.5 billion in a third plant by 2028 using its own funds.

  4. 4

    The typhoid conjugate vaccine received WHO prequalification in August 2026 and is planned for supply in 2027, while the pentavalent meningococcal vaccine targets public-market entry in 2028.

  5. 5

    A 2025 report said cholera vaccines accounted for 99% of revenue, and first-half 2026 revenue fell 35.5% and operating profit fell 61.7% on a base effect, highlighting single-product dependence and quarterly volatility as bearish factors.

02

Business structure

EuBiologics develops the oral cholera vaccine Euvichol family and supplies it to international agencies such as UNICEF and WHO. Its main formulations are Euvichol-Plus and the improved Euvichol-S, which raised production yield by 40% and received additional WHO prequalification (PQ).

A 2025 report said cholera vaccines accounted for 99% of revenue in the first quarter of that year, with UNICEF as the main buyer.

The company forecasts international demand through regular conference calls and sells mainly through public procurement, while private markets in parts of the Middle East are served through local partners.

On the production side, it used its second plant to lift annual cholera vaccine capacity from about 33 million doses to about 90 million.

The pipeline includes the typhoid conjugate vaccine EuTYPH-C, the pentavalent meningococcal vaccine EuMCV5, shingles (EuHZV) and RSV vaccines, and an Alzheimer's therapeutic vaccine in research. The typhoid vaccine received WHO PQ in August 2026 and is planned for supply from 2027.

The meningococcal vaccine is in clinical trials, targeting public-market entry in 2028. In competition, Sanofi's Indian unit Shantha Biotec withdrew its Shan-Chol cholera vaccine from the public market in 2024, easing supply competition.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩41.1B₩18.9B46.0%
2025Q4₩32.3B₩13.6B42.1%
2026Q1₩15.6B₩2.2B14.0%
2026Q2₩33.2B₩8.6B25.8%
2026Q3₩49.6B₩21.9B44.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩55.5B-₩3.8B-₩1.1B−6.8%−0.9%35.7%
2023₩69.4B₩7.7B-₩13.9B11.1%−12.5%44.8%
2024₩96B₩34.3B₩19B35.7%14.4%53.1%
2025₩149.2B₩60.7B₩41.3B40.7%23.5%37.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 55.5 billion in 2022 to KRW 69.4 billion in 2023 (up 25.1% year on year), KRW 96 billion in 2024 (up 38.4%) and KRW 149.2 billion in 2025 (up 55.4%). Revenue has grown for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022 to 2025 period.

Operating results moved from an operating loss of KRW 3.77 billion in 2022 to an operating profit of KRW 7.7 billion in 2023, a swing to profit, then KRW 34.3 billion in 2024 (up 345.8%) and KRW 60.7 billion in 2025 (up 76.8%), which means operating profit has risen for two consecutive years from 2024 to 2025.

The operating margin went from -6.8% in 2022 to 11.1% in 2023, 35.7% in 2024 and 40.7% in 2025. In an early 2026 report, the CEO attributed the 2025 improvement to higher cholera vaccine shipments and a more stable production plant.

Profit attributable to controlling shareholders moved from a loss of KRW 1.1 billion in 2022 and a loss of KRW 13.9 billion in 2023, which widened the loss, to a profit of KRW 19 billion in 2024 (a swing to profit) and KRW 41.3 billion in 2025 (up 117.3%).

Net income including non-controlling interests was a loss of KRW 3.44 billion in 2022, a loss of KRW 15.4 billion in 2023, a profit of KRW 19 billion in 2024 and KRW 41.3 billion in 2025.

On a quarterly basis, revenue was KRW 41.1 billion with operating profit of KRW 18.9 billion in the third quarter of 2025, then KRW 32.3 billion and KRW 13.6 billion in the fourth quarter (revenue down 21.4% from the prior quarter).

The first quarter of 2026 was the trough, at KRW 15.6 billion in revenue and KRW 2.19 billion in operating profit. Third-quarter 2026 revenue of KRW 49.6 billion rose 20.6% year on year, and operating profit of KRW 21.9 billion rose 15.6%.

Before the release, KB Securities had estimated third-quarter revenue of KRW 48.5 billion and operating profit of KRW 20.2 billion, and SangSangin Securities had estimated KRW 47.9 billion and KRW 21.1 billion, and the disclosed figures came in above both.

Brokers attributed the first-half decline to a base effect from a temporary surge in cholera vaccine exports in the first half of 2025. Profit attributable to controlling shareholders over the latest four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 43.3 billion.

Total equity at the end of 2025 was KRW 175.4 billion, all attributable to controlling shareholders, and total liabilities were KRW 64.9 billion. The debt ratio fell from 53.1% in 2024 to 37.0% in 2025, and operating cash flow rose from KRW 6.44 billion in 2022 to KRW 49.1 billion in 2025.

05

Industry analysis

EuBiologics' core market is publicly procured vaccines bought by international agencies. Cholera vaccine demand moves with the purchasing programs of bodies such as UNICEF and WHO.

A 2025 report said the five-year purchasing budget of Gavi rose from USD 8.8 billion in the Gavi 5.0 period to USD 9 billion in Gavi 6.0, and brokers viewed this as easing concerns about revenue decline. Competition in cholera vaccines changed after Shantha Biotec withdrew Shan-Chol in 2024.

In early 2026, the CEO said some Indian suppliers could enter the market, but their volumes would be limited.

Unlike CDMO-focused listed peers in the same sector such as Samsung Biologics, the company's business centers on its own vaccine products sold through international public procurement, while contract manufacturing is described as a secondary activity.

Estimates put the global meningococcal vaccine market at roughly KRW 35 trillion (2025 report). The company's own materials describe it as holding a near-monopoly supplier position in global public procurement.

In the cycle, the first half of 2025 saw an export surge, the first half of 2026 saw an adjustment, and the second half of 2026 recovered. Whether this reflects temporary swings in public procurement volumes or a structural change will need to be confirmed through quarterly results from 2027 onward.

06

Outlook

The company's stated medium-term plan is to launch typhoid and meningococcal vaccines by 2028 and launch RSV and shingles vaccines around 2030.

The typhoid vaccine received WHO PQ in August 2026 and is planned for supply in 2027, and KB Securities viewed the existing cholera public-procurement experience and supply chain as a strength that can be used.

The meningococcal vaccine EuMCV5 completed Phase 1 in Korea and was in Phase 2/3 trials in Africa as of a 2025 report. On production, cholera capacity has risen to about 90 million doses, but the order backlog rose only slightly, from 72.02 million doses in July 2025 to 72.1 million doses in July 2026.

The third plant is planned to take about KRW 111.5 billion in phased investment through 2028, and reports say it will be funded from the company's own resources without external financing.

In a 2025 report, an executive said sequential launches of public vaccines could lift revenue to around KRW 200 billion within several years. That is a management aspiration rather than a confirmed forecast.

In an October 2026 report, KB Securities said the third plant could serve as a hub producing several vaccines beyond cholera. Premium vaccines remain in clinical development, and the company said in a 2025 report that it is considering licensing out because Phase 3 costs are high.

The next checkpoints are the start of typhoid vaccine supply, changes in the order backlog, and the construction timing of the third plant.

07

Valuation

PER
6.8×
PBR
1.4×
ROE
22.4%
EPS
₩1,186
BPS
₩5,828
Dividend per share
₩0

The stock trades at a premium to net asset value, with the price-to-book ratio above 1x.

Before the swing to operating profit in 2023, and while controlling-shareholder losses continued through 2023, earnings-based multiples could not be calculated; since 2024, rising profit has brought the stock into a range where earnings multiples can be computed.

Profit attributable to controlling shareholders over the latest four quarters totals KRW 43.3 billion, which is above the KRW 41.3 billion reported for full-year 2025. The shareholder return ratio is low, so cash is concentrated in capital spending such as the third plant.

SangSangin Securities said in an October 27, 2026 report that it maintained a target price of KRW 12,000. KB Securities did not disclose an investment rating or target price in its October 2026 report.

Because the quarterly recovery covers only two quarters so far, how earnings multiples are read will depend on whether profit continues into 2027 and beyond.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Clear improvement in earnings power

Revenue of KRW 149.2 billion and a 40.7% operating margin in 2025 are far from the operating-loss years of 2022. Operating cash flow rose from KRW 6.44 billion in 2022 to KRW 49.1 billion in 2025, and the debt ratio fell to 37.0%. Funding the third plant from internal cash also points to financial capacity.

Capacity and a new vaccine pipeline

Cholera capacity expanded to about 90 million doses per year using the second plant. The typhoid vaccine received WHO PQ in August 2026 and is planned for 2027 supply, and the meningococcal vaccine targets public-market entry in 2028. KB Securities expects these vaccines to become growth drivers beyond a single public-sector product.

Public procurement base and purchasing budget

The company says its WHO-certified cholera vaccine and international public-procurement experience give it a supply position. A 2025 report said the same supply chain can serve the typhoid vaccine. Brokers viewed Gavi's budget increase from USD 8.8 billion to USD 9 billion as a positive.

09

Bear factors

Single-product dependence and export swings

A 2025 report said cholera vaccines made up 99% of revenue. Sales move sharply with international purchase volumes, and first-half 2026 revenue fell 35.5% and operating profit fell 61.7% on lower exports. Contribution from new products can only be confirmed from 2027 onward.

High quarterly volatility

First-quarter 2026 revenue fell 51.6% from the prior quarter to KRW 15.6 billion. The cholera order backlog rose only slightly, from 72.02 million doses in July 2025 to 72.1 million in July 2026. Because supply concentrates in the second half, quarterly results can swing widely.

Investment burden and development costs

About KRW 111.5 billion for the third plant will be spent in phases through 2028, which could weigh on fixed costs until utilization rises. R&D spending in 2023 and 2024 was KRW 25.7 billion, excluding KRW 3.9 billion of government subsidies.

Phase 3 costs for premium vaccines are high enough that the company is considering licensing, leaving uncertainty.

10

Risk factors

Policy and procurement risk

Purchasing budgets and supply formats set by international agencies are outside the company's control. A 2025 report said a possible shift to two doses per person in a cholera campaign could be a positive for sales. Policy changes feed directly into volumes and therefore into reported results.

Competition and supplier structure risk

Supplier numbers fell after Shantha Biotec's withdrawal, but Indian suppliers could still enter the cholera market. The company says their volumes would be limited, yet changes in rival pricing or volumes could affect Euvichol share. Whether shipments keep recovering after the switch to Euvichol-S also needs to be confirmed.

Development and capex risk

Typhoid, meningococcal, RSV and shingles vaccines are at early stages after certification or in clinical trials. If trial results disappoint or supply schedules slip, new revenue will be delayed. If demand does not grow as expected, the third plant could become a fixed-cost burden.

11

What to watch next

  1. First half of 2027

    Confirm the start of EuTYPH-C typhoid vaccine supply and the size of first shipments. Whether the 2027 supply plan is met marks the starting point of new revenue.

  2. Early 2027 to end of March 2027

    The fourth-quarter 2026 results and the 2026 annual business report will be released. In this next periodic filing, check whether the full-year 2026 operating margin holds near the 40.7% recorded in 2025.

  3. Mid-May 2027

    First-quarter 2027 results and the quarterly report are due. Check whether the first quarter after typhoid supply begins shows any revenue contribution.

  4. First half of 2027

    Check whether construction of the third plant starts. Reports say groundbreaking is planned for the first half of 2027, and the size and schedule of investment spending are the items to track.

  5. 2028

    This is the target year for EuMCV5 pentavalent meningococcal vaccine entry into public markets, and also the target for completing the third-plant investment.

12

Overall view

EuBiologics' operating profit turned positive in 2023 and rose with revenue through 2025, when the operating margin reached 40.7%, supported by cholera vaccine supply to international agencies.

Revenue bottomed at KRW 15.6 billion in the first quarter of 2026 and then recovered in the second and third quarters, with third-quarter revenue of KRW 49.6 billion and operating profit of KRW 21.9 billion.

Improvements in operating cash flow and the debt ratio are financial strengths, and funding the third plant from internal cash is a notable feature. On the other side, most revenue still relies on cholera vaccines, and quarterly results can swing sharply on export base effects as seen in the first half of 2026.

Whether typhoid supply in 2027 and meningococcal market entry in 2028 turn into actual revenue is the key variable for reading medium-term results. On valuation, the stock trades at a premium to net asset value, and broker target prices are cited only with their source and date.

The next checkpoint is whether the fourth-quarter results and the full-year operating margin hold in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hankyung.com
  2. comp.wisereport.co.kr
  3. openbizdata.com
  4. pharm.edaily.co.kr
  5. m.news.nate.com
  6. thebionews.net
  7. comp.fnguide.com
  8. thebionews.net
  9. pharm.edaily.co.kr
  10. app.rndcircle.io
  11. pharmnews.com
  12. press9.kr
  13. getnews.co.kr
  14. medipana.com
  15. alphabiz.co.kr
  16. medipana.com
  17. hankyung.com
  18. view.asiae.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis